Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
| Autor: | Sashiananthan Ganesananthan, Zaheer Yousef, Nisar Shah, Parin Shah, Hossam Elsayed, Julie Phillips, Ann Parkes, Angharad Morgan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Open Heart, Vol 7, Iss 2 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2020-0013 2053-3624 |
| DOI: | 10.1136/openhrt-2020-001305 |
| Popis: | Background Sacubitril/valsartan is an effective treatment for heart failure with reduced ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or impact in real-world practice. The aim of this study was to describe our routine clinical experience of switching otherwise optimally treated patients with HFrEF to sacubitril/valsartan with respect to patient outcomes such as quality of life (QoL) and echocardiographic variables.Methods and results From June 2017 to May 2019, 80 consecutive stable patients with HFrEF on established and maximally tolerated guideline-directed HF therapies were initiated on sacubitril/valsartan with bimonthly uptitration. Clinical assessment, biochemistry, echocardiography and QoL were compared pretreatment and post-treatment switching. We were able to successfully switch 89% of patients from renin–angiotensin axis inhibitors to sacubitril/valsartan (71 of 80 patients). After 3 months of switch therapy, we observed clinically significant and incremental improvements in blood pressure (systolic blood pressure 123 vs 112 mm Hg, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|